Related Experiment Video
Updated: Jun 6, 2026
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Anti-CTLA-4 antibody adjuvant therapy in melanoma
Alexander M M Eggermont1, Alessandro Testori, Michele Maio
1Institut d'Oncologie Gustave Roussy, Villejuif, France. alexander.eggermont@igr.fr
Abstract:
Thus far the development of adjuvant therapies in melanoma has suffered greatly from the lack of effective drugs in stage IV melanoma. Chemotherapy, cytokines, vaccines, and combinations of drugs have been used with minimal success. This has led to adjuvant therapies that are not used uniformly or widely because of the rather marginal benefits, as no consistent and clinically significant impact on survival has been demonstrated. A new development for interferon-based adjuvant therapy seems to be the observation that better effects are observed in patients with lower tumor load and in patients with an ulcerated primary melanoma. A benefit for patients with more advanced lymphnodal involvement is quite unsure, clearly requiring new drugs to be explored. A new era in the treatment of melanoma treatment has arrived with the anti-cytoxic T-lymphocyte antigen-4 (anti-CTLA-4) monoclonal antibodies. The randomized trial in advanced metastatic melanoma demonstrated a clear benefit with prolongation of survival. The anti-CTLA-4 monoclonal antibody ipilimumab has finally changed the landscape. It is therefore only logical that a worldwide adjuvant trial with ipilimumab versus placebo, the European Organization for Research and Treatment of Cancer (EORTC) 18071, is ongoing in patients with lymph node metastases, and that another adjuvant trial with ipilimumab compared to high-dose interferon (HDI) is planned in the United States. The EORTC 18071 trial will reach full accrual in 2011 and thus results are expected in 2013 or 2014.
Insights
Adjuvant therapies for stage IV melanoma have shown limited success. New treatments like anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) antibodies offer improved survival benefits for melanoma patients.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Research
Background:
- Adjuvant therapies for stage IV melanoma have historically yielded minimal success.
- Previous treatments including chemotherapy and cytokines showed limited impact on survival.
- Interferon-based therapies show potential in specific patient subgroups, but new drugs are needed for advanced disease.
Purpose of the Study:
- To evaluate the efficacy of novel adjuvant therapies in melanoma.
- To investigate the role of anti-cytotoxic T-lymphocyte antigen-4 (anti-CTLA-4) monoclonal antibodies in melanoma treatment.
- To assess the impact of ipilimumab on survival in patients with lymph node metastases.
Main Methods:
- A worldwide adjuvant trial (EORTC 18071) comparing ipilimumab to placebo in patients with lymph node metastases.
- An upcoming adjuvant trial comparing ipilimumab to high-dose interferon (HDI) in the United States.
- Utilizing anti-CTLA-4 monoclonal antibodies as a new therapeutic strategy.
Main Results:
- Randomized trials in advanced metastatic melanoma demonstrated clear survival benefits with anti-CTLA-4 antibodies.
- Ipilimumab has significantly altered the treatment landscape for melanoma.
- The EORTC 18071 trial is expected to provide crucial data on ipilimumab's efficacy in the adjuvant setting.
Conclusions:
- Anti-CTLA-4 monoclonal antibodies, such as ipilimumab, represent a significant advancement in melanoma treatment.
- Ongoing adjuvant trials are critical for establishing the role of ipilimumab in preventing melanoma recurrence.
- New therapeutic strategies are essential to improve outcomes for patients with advanced melanoma.
